BioViva Science

Executive Summary

BioViva Science is a privately-held biotechnology company headquartered in Boca Raton, Florida, founded in 2015 with a mission to extend healthy human lifespan through gene therapy. The company leverages adeno-associated virus (AAV) and cytomegalovirus (CMV) viral vector platforms to develop treatments for aging-associated diseases, such as cellular senescence and telomere shortening. While still in early stages—no disclosed funding rounds or clinical pipeline details—the company has gained attention for its unconventional approach, including controversial self-experimentation by its CEO, Elizabeth Parrish, who underwent gene therapy in 2015. BioViva's focus on longevity and disease reversal positions it in a rapidly growing but competitive field, though its lack of transparent clinical data and regulatory milestones makes it a high-risk, high-reward proposition.

Upcoming Catalysts (preview)

• TBDPublication of Preclinical Data on Telomerase Gene Therapy Candidate60% success
• Q3 2026Announcement of Series A Funding or Strategic Partnership50% success
• Q4 2026Regulatory Clearance (IND) for First-in-Human Clinical Trial35% success